Membranoproliferative glomerulonephritis secondary prevention: Difference between revisions
Created page with "__NOTOC__ Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{Membranoproliferative glomerulonephritis..." |
Aditya Ganti (talk | contribs) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Membranoproliferative glomerulonephritis}} | {{Membranoproliferative glomerulonephritis}} | ||
{{CMG}} ; {{AE}} | |||
== Overview == | |||
Effective measures for the secondary prevention of MPGN include initiating treatment to halt disease progression to ESRD. | |||
== Secondary prevention == | |||
Effective measures for the secondary prevention of MPGN include initiating treatment to halt disease progression to ESRD. Common medications recommended for secondary prevention include:<ref>{{Cite journal|last=Kambiz Zandi-Nejad, and Barry M. Brenner|first=|date=|title=Primary and secondary prevention of chronic kidney disease|url=|journal=Journal of hypertension|volume=23|pages=10|via=}}</ref> | |||
* [[ACE inhibitor|Angiotensin-converting enzyme (ACE) inhibitors]] | |||
* [[Angiotensin II receptor antagonist|Angiotensin-receptor blockers]] | |||
* Combined ACE inhibition and angiotensin receptor antagonism | |||
* Dietary protein restriction | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Nephrology]] | [[Category:Nephrology]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Latest revision as of 20:30, 6 August 2018
|
Membranoproliferative glomerulonephritis Microchapters |
|
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranoproliferative glomerulonephritis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis secondary prevention |
|
FDA on Membranoproliferative glomerulonephritis secondary prevention |
|
CDC on Membranoproliferative glomerulonephritis secondary prevention |
|
Membranoproliferative glomerulonephritis secondary prevention in the news |
|
Blogs on Membranoproliferative glomerulonephritis secondary prevention |
|
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
|
Risk calculators and risk factors for Membranoproliferative glomerulonephritis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:
Overview
Effective measures for the secondary prevention of MPGN include initiating treatment to halt disease progression to ESRD.
Secondary prevention
Effective measures for the secondary prevention of MPGN include initiating treatment to halt disease progression to ESRD. Common medications recommended for secondary prevention include:[1]
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin-receptor blockers
- Combined ACE inhibition and angiotensin receptor antagonism
- Dietary protein restriction
References
- ↑ Kambiz Zandi-Nejad, and Barry M. Brenner. "Primary and secondary prevention of chronic kidney disease". Journal of hypertension. 23: 10.